“There’s a lot of potential for growth that we see both within the kidney space and without. Truly any drug that is administered chronically and that has a narrow theraapeutic range is a drug that we think can benefit from our platform.
There’s more information at www.dosisinc.com.
You can find us at Techstination.com. I’m Fred Fishkin.
| Categories: | General Technology News |
|---|